Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019


#109266

103pages

GlobalData

$ 3995

In Stock



GlobalData, the industry analysis specialist, has released its new report, Hepatitis B Therapeutics Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalDatas analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.

Scope

The report provides information on the key drivers and challenges of the hepatitis B therapeutics market. Its scope includes 

  • Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan hepatitis B therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HBsAg release blocker, HBV DNA polymerase inhibitor, HBV DNA polymerase inhibitor and immunomodulator, HBV DNA polymerase inhibitor and microtubule assembly inhibitor, HBV therapeutic vaccine, HBV therapeutic vaccine and HBV DNA polymerase inhibitor, Hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, Immunomodulator, Protease inhibitor and others.
  • Analysis of the current and future competition in the seven key countries hepatitis B therapeutics market. Key market players covered are GlaxoSmithKline, Bristol-Myers Squibb, Daewoong Pharmaceutical Co., Ltd., Chongqing Jiachen Biotechnology Ltd, Chongqing Tongjunge Co., Ltd., LG Life Sciences, Ltd, Bristol-Myers Squibb Company, Phytrix Inc., Medivir AB, AiCuris GmbH & Co. KG, Gilead Sciences, Inc., VectorLogics, Inc., Genexine Co., Ltd., GenPhar, Inc., Cytheris SA, Bolder Biotechnology, Inc, ImQuest Life Sciences, Aduro BioTech, Agenix Limited, Xenetic Biosciences plc, MOLOGEN AG, NanoBio Corporation, Inbiopro Solutions Pvt. Ltd., Gilead Sciences, Merck & Co. Inc. and Novartis AG, 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hepatitis B therapeutics market.
  • Analysis of key recent licensing and partnership agreements in hepatitis B therapeutics market
Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global hepatitis B therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis B therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global hepatitis B therapeutics market landscape? Identify, understand and capitalize.
Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
Table of Content

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Hepatitis B Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Disease Burden 10
2.4 Etiology 11
2.5 Symptoms 13
2.6 Diagnosis 13
2.7 Pathophysiology 16
2.8 Treatment and Management Pattern 19
2.9 GlobalData Pipeline Report Guidance 22

3 Hepatitis B Therapeutics - Market Characterization 23
3.1 Hepatitis B Therapeutics Market Size (2006 - 2011) - Global 23
3.2 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Global 24
3.3 Hepatitis B Therapeutics Market Size (2006 - 2011) - The US 25
3.4 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The US 26
3.5 Hepatitis B Therapeutics Market Size (2006 - 2011) - France 27
3.6 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - France 28
3.7 Hepatitis B Therapeutics Market Size (2006 - 2011) - Germany 29
3.8 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Germany 30
3.9 Hepatitis B Therapeutics Market Size (2006 - 2011) - Italy 31
3.10 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Italy 32
3.11 Hepatitis B Therapeutics Market Size (2006 - 2011) - Spain 33
3.12 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Spain 34
3.13 Hepatitis B Therapeutics Market Size (2006 - 2011) - The UK 35
3.14 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The UK 36
3.15 Hepatitis B Therapeutics Market Size (2006 - 2011) - Japan 37
3.16 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Japan 38
3.17 Drivers and Barriers for the Hepatitis B Therapeutics Market 39
3.17.1 Drivers for the Hepatitis B Therapeutics Market 39
3.17.2 Barriers for the Hepatitis B Therapeutics Market 39
3.18 Opportunity and Unmet Need 40
3.19 Key Takeaway 41

4 Hepatitis B Therapeutics - Competitive Assessment 42
4.1 Overview 42
4.2 Strategic Competitor Assessment 42
4.3 Product Profile for the Major Marketed Drugs 43
4.3.1 Intron A (interferon alpha 2b) 43
4.3.2 Pegasys (peginterferon alfa-2a) 44
4.3.3 Baraclude (entecavir) 45
4.3.4 Tyzeka (telbivudine) 47
4.3.5 Hepsera (adevofir) 50
4.3.6 Epivir-HBV (lamivudine) 52
4.3.7 Viread (tenovofir) 54
4.4 Key Takeaway 56

5 Hepatitis B Therapeutics - Pipeline Assessment 57
5.1 Overview 57
5.2 Strategic Pipeline Assessment 57
5.3 Hepatitis B Therapeutics - Pipeline Analysis by Clinical Phase of Development 57
5.3.1 Hepatitis B Therapeutics - Phase III Clinical Pipeline 58
5.3.2 Hepatitis B Therapeutics - Phase II Clinical Pipeline 59
5.3.3 Hepatitis B Therapeutics - Phase I Pipeline 60
5.3.4 Hepatitis B Therapeutics - Preclinical Phase Pipeline 60
5.3.5 Hepatitis B Therapeutics - NA Phase Pipeline 60
5.4 Hepatitis B Therapeutics - Pipeline by Mechanism of Action 61
5.5 Technology Trends Analytical Framework 62
5.6 Key Takeaway 62

6 Hepatitis B Therapeutics - Clinical Trials Mapping 63
6.1 Overview 63
6.2 Clinical Trials by Region/Country (The US, EU5 and Japan) 63
6.3 Clinical Trials by Phase of Clinical Development 64
6.4 Clinical Trials by Trial Status 65
6.5 Prominent Sponsors 66
6.6 Clinical Trials by Sponsors 67
6.7 Top Companies Participating in Hepatitis B Therapeutics Clinical Trials 68
6.8 Key Takeaway 69

7 Hepatitis B Therapeutics - Strategic Assessment 70
7.1 Key Events Impacting the Future Market 70
7.2 Future Market Competition Scenario 70

8 Hepatitis B Therapeutics - Future Players 72
8.1 Introduction 72
8.2 Company Profiles 72
8.2.1 Bristol-Myers Squibb Company 72
8.2.2 Gilead Sciences 74
8.2.3 GlaxoSmithKline Plc 75
8.2.4 F. Hoffmann-La Roche 77
8.2.5 Merck & Co. Inc. 78
8.2.6 Novartis AG 79
8.3 Other Companies 80
8.4 Key Takeaway 84

9 Hepatitis B Therapeutics - Licensing & Partnership Deals 85

10 Hepatitis B Therapeutics - Appendix 96
10.1 Market Definitions 96
10.2 Abbreviations 96
10.3 Research Methodology 98
10.3.1 Coverage 98
10.3.2 Secondary Research 98
10.3.3 Forecasting 99
10.3.4 Primary Research 101
10.3.5 Expert Panel Validation 101
10.4 Contact Us 101
10.5 Disclaimer 102
10.6 Bibliography 102

Table 1: Hepatitis B - Nomenclature of Hepatitis B 7
Table 2: Hepatitis B - Laboratory Nomenclature 15
Table 3: Hepatitis B - Approved Vaccines for Hepatitis B 19
Table 4: Hepatitis B - Approved Drugs for Hepatitis B 19
Table 5: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011 23
Table 6: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019 24
Table 7: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011 25
Table 8: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019 26
Table 9: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011 27
Table 10: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019 28
Table 11: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 29
Table 12: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 30
Table 13: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 31
Table 14: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 32
Table 15: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 33
Table 16: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 34
Table 17: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 35
Table 18: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 36
Table 19: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 37
Table 20: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 38
Table 21: Histological Improvement and Change in Ishak Fibrosis Score at Week 52 (007 GLOBE Study) 49
Table 22: The Results for Measures of Response Included Change in Serum HBV DNA, Change in ALT, HBeAg loss and HBeAg Seroconversion (437 Only) 51
Table 23: Changes in Ishak Fibrosis Score at Week 48 51
Table 24: Histologic Response at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo 53
Table 25: HBeAg Seroconversion at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo 53
Table 26: Clinical Study Results - Viread 55
Table 27: Hepatitis B Therapeutics Market, Phase III Pipeline, 2011 58
Table 28: Hepatitis B Therapeutics Market, Phase II Pipeline, 2011 59
Table 29: Hepatitis B Therapeutics Market, Phase I Pipeline, 2011 60
Table 30: Hepatitis B Therapeutics Market, Preclinical Phase Pipeline, 2011 60
Table 31: Hepatitis B Therapeutics Market, NA Phase Pipeline, 2011 60
Table 32: Hepatitis B Therapeutics, Global, Clinical Trials, 2011 63
Table 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2011 64
Table 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development, 2011 65
Table 35: Hepatitis B Therapeutics, Global, Prominent Sponsors, 2011 66
Table 36: Hepatitis B Therapeutics, Global, Overall Sponsors, 2011 67
Table 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011 68
Table 38: Bristol-Myers Squibb Company - Pipeline, 2011 74
Table 39: Gilead Sciences - Pipeline, 2011 75
Table 40: GlaxoSmithKline Plc. - Pipeline, 2011 76
Table 41: Other Companies - Hepatitis B Therapeutics, 2011 80
Table 42: Hepatitis B Therapeutics, Global, Deals - 2011 85
Figure 1: Genotype of Hepatitis B Virus and its Geographical Distribution 7
Figure 2: Hepatitis B - Prevalence of HBV Infection in the World by Country 8
Figure 3: Hepatitis B - Areas and Features of Hepatitis B Prevalence 9
Figure 4: Geographic Patterns of Hepatitis B Disease Burden 10
Figure 5: Structure of Hepatitis B Virus 11
Figure 6: Summary of Hepatitis B Virus Characteristics 12
Figure 7: Hepatitis B - Interpretation of Hepatitis B Virus Serology 15
Figure 8: Hepatitis B - Life Cycle of HBV 17
Figure 9: Hepatitis B - Spectrum of Liver Disease After HBV Infection 18
Figure 10: Hepatitis B - Childhood Vaccination Schedule 21
Figure 11: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011 23
Figure 12: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019 24
Figure 13: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011 25
Figure 14: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019 26
Figure 15: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011 27
Figure 16: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019 28
Figure 17: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 29
Figure 18: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 30
Figure 19: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 31
Figure 20: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 32
Figure 21: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 33
Figure 22: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 34
Figure 23: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 35
Figure 24: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 36
Figure 25: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 37
Figure 26: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 38
Figure 27: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market 40
Figure 28: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Therapeutics, 2011 43
Figure 29: Hepatitis B Therapeutics Pipeline by Phase of Clinical Development, 2011 57
Figure 30: Hepatitis B Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011 61
Figure 31: Technology Trends Analytics Framework, 2011 62
Figure 32: Hepatitis B Therapeutics, Global, Clinical Trials by Country, 2011 63
Figure 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2011 64
Figure 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 65
Figure 35: Hepatitis B Therapeutics, Global, Prominent Sponsors (%), 2011 66
Figure 36: Hepatitis B Therapeutics, Global, Overall Sponsors (%), 2011 67
Figure 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011 68
Figure 38: Hepatitis B Therapeutics Market, Drivers and Restraints, 2011 70
Figure 39: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2011 70
Figure 40: Hepatitis B Therapeutics Market, Clinical Pipeline by Company, 2011 72
Figure 41: GlobalData Market Forecasting Model 100